Latest Daiichi Sankyo Company Limited Stories
TOKYO and SAN DIEGO, Nov.
- Committee votes 9 to 1 to recommend approval of once-daily SAVAYSA for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) TOKYO,
SAN DIEGO, Oct.
TOKYO and SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- On Friday October 10, U.S.
Results presented during ESC Congress 2014 Clinical Trial Update Hot Line session BARCELONA, Spain, Sept.
First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion PARSIPPANY, N.J.,
- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials(1,2,3,4) TOKYO,
TOKYO, March 19, 2014 /PRNewswire/ -- Astellas Pharma Inc.
- totally perplexed and mixed up.